BioNexus Gene Lab

BioNexus Gene Lab Capital Intensity

The Capital Intensity Ratio of BioNexus Gene Lab (BGLC) as of Oct 29, 2026 is 124.62 %. In the previous year, Capital Intensity Ratio was 109.71 % — a change of 13.59% (higher).

Capital Intensity

124.62 %

YoY

13.59%

Last updated:

Capital Intensity Ratio of BioNexus Gene Lab is 2025 124.62 % . Capital Intensity Ratio of BioNexus Gene Lab was 2024 109.71 % . It decreases by 13.59% higher compared to the previous year.

The BioNexus Gene Lab Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
778.15 USD
Jan 1, 2019
969.82 USD
Jan 1, 2020
88.81 USD
Jan 1, 2021
71.65 USD
Jan 1, 2022
79.97 USD
Jan 1, 2023
116.67 USD
Jan 1, 2024
109.71 USD
Jan 1, 2025
124.62 USD
The BioNexus Gene Lab Capital Intensity history
YEARCapital IntensityYoY
124.62 %+13.59%
109.71 %-5.97%
116.67 %+45.89%
79.97 %+11.62%
71.65 %-19.32%
88.81 %-90.84%
969.82 %+24.63%
778.15 %-34.17%
1,182.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioNexus Gene Lab Stock analysis

What does BioNexus Gene Lab do? BioNexus Gene Lab Corp. develops and markets non-invasive blood tests for early disease detection, analyzing RNA changes to assess risks for over 11 diseases. The company’s subsidiary, Bionexus Gene Lab Sdn. Bdh., supports these operations. Products are sold to healthcare providers and diagnostic centers seeking advanced, non-invasive testing solutions. The firm targets medical professionals and institutions focused on personalized health management through functional genomics applications. The company generates revenue through the sale of its RNA-based blood tests, which are marketed as tools for early disease risk assessment. Healthcare institutions and diagnostic service providers purchase these tests to enhance their diagnostic capabilities. The focus on non-invasive methods aligns with growing demand for patient-friendly diagnostic technologies in the molecular diagnostics sector. BioNexus Gene Lab Corp. operates with a small team of 5 full-time employees, emphasizing efficiency in product development and marketing. The subsidiary Bionexus Gene Lab Sdn. Bdh. facilitates local operations, though specific market segments are not detailed beyond healthcare providers and diagnostic centers. Revenue streams are derived solely from test sales, with no mention of additional services or partnerships. BioNexus Gene Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioNexus Gene Lab stock

Capital Intensity Ratio of BioNexus Gene Lab is 124.62 % in 2025.

Capital Intensity Ratio of BioNexus Gene Lab changed from 109.71 % to 124.62 %, representing a 13.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio BioNexus Gene Lab since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's BioNexus Gene Lab with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BioNexus Gene Lab

All Key Metrics — BioNexus Gene Lab